NOTICE OF RESULTS FOR YEAR ENDED 31 MARCH 2020

RNS Number : 7664Y

Eco Animal Health Group PLC

11 September 2020

 

ECO Animal Health Group plc

("ECO" or the "Group")

(AIM: EAH)

NOTICE OF RESULTS FOR YEAR ENDED 31 MARCH 2020

ECO Animal Health Group plc (the "Group") announces that the Group intends to publish its annual audited accounts for the year ended 31 March 2020 during November and prior to 30 November 2020.

The Group was granted an up to two month extension to the publication timetable in order to manage additional difficulties arising from auditing the Group's international operations during the Covid-19 pandemic restrictions and against the backdrop of new auditors and new accounting policies adopted at the time of the most recent interim report.

Consistent with the Government extension to the deadline for filing accounts at Companies House, the deadline for holding an Annual General Meeting has also been extended and must now be held before 31 December 2020.  As is customary, the Group will give notice of the date for holding the AGM at the same time as publishing its annual audited accounts.

The Group provided a Trading update on 10 June 2020, noting that the Group had seen strong financial performance in the year ended 31 March 2020 and that Revenue and EBITDA were expected to be significantly ahead of market expectations.  A current year trading update will be provided after the half year ending on 30 September 2020.

Contacts:  

ECO Animal Health Group plc Marc Loomes (CEO) Christopher Wilks (CFO)	020 8447 8899
IFC Advisory Graham Herring Zach Cohen	020 3934 6630
N+1 Singer (Nominated Adviser & Joint Broker) Mark Taylor Peter Steel Alex Bond	020 7496 3000
Peel Hunt LLP (Joint Broker) James Steel Dr Christopher Golden	020 7418 8900

ECO Animal Health Group plc ("ECO" or "the "GROUP") researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.

 

END

 

 

NORBGGDCRGBDGGB